Retraction of “Promising Experimental Anti-SARS-CoV‑2 Agent “SLL-0197800”: The Prospective Universal Inhibitory Properties against the Coming Versions of the Coronavirus”
Saved in:
| Main Authors: | Amgad M. Rabie, Marwa A. Abdel-Dayem, Mohnad Abdalla |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Chemical Society
2025-03-01
|
| Series: | ACS Omega |
| Online Access: | https://doi.org/10.1021/acsomega.5c01901 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cholinesterase Inhibitory Activity of Paeoniflorin: Molecular Dynamics Simulation, and In Vitro Mechanistic Investigation
by: Mohnad Abdalla, et al.
Published: (2024-01-01) -
PERITONEAL MESOTHELIOMA AS A CO-MALIGNANCY IN A PATIENT WITH CLL/SLL: CASE REPORT
by: Satı Betül Beydilli, et al.
Published: (2024-12-01) -
The Coming Coronavirus Crisis: What Can We Learn?
by: Matteo Lucchese, et al.
Published: (2020-04-01) -
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
by: Mazyar Shadman, et al.
Published: (2025-08-01) -
Sll1725, an ABC transporter in Synechocystis sp. PCC 6803 for the detoxification of cadmium ion stress
by: Gang Ruan, et al.
Published: (2025-07-01)